Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 8, 1997

View Archived Issues

Vical's Allovectin-7 enters phase II for head and neck cancer

Cambridge NeuroScience moves CNS-5161 to clinical trials

ENDOcare's device for abnormal uterine bleeding enters clinical trials

Roche terminates antisense collaboration with Hybridon

Sequana and Glaxo Wellcome near discovery of diabetes genes

Beckman to acquire Coulter

Boehringer Mannheim prepares MMP inhibitors

New antiandrogenic compounds prepared at Roussel Uclaf

GH secretagogues claimed by Novo Nordisk

Aricept now available in Canada

Novel integrin receptor antagonists from DuPont Merck

GeneMedicine begins phase I testing of IL-2 Cancer Gene Medicine

Celltech prepares improved PDE IV inhibitors

Triangle completes acquisition of Avid, rights to DMP-450

FDA grants expedited review for SalEst system

FDA advisory committee recommends thalidomide for approval

Breakthrough discovery in receptor function reported by Acadia

Genentech discontinues IGF-I development for type I and II diabetes

Centocor will manufacture ID Biomedical's Rapid MRSA test kit

Roche subscribes to Easy Access for Affymetrix GeneChip

Sleep-promoting effects of L-846 demonstrated in insomniac patients

Voglibose preclinical results described at Japanese congress

Anti-HSV compounds with a novel mechanism of action

Clinical evaluation planned for anti-HIV compound with novel mechanism of action

Uroselective alpha1-adrenoceptor antagonists for BPH

In vitro pharmacological profile of KRH-594

Animal strain of hepatitis E virus isolated at NIAID

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...